Shaohui Yang1, Luorui Song1, Lei Zhao2, Pingshuan Dong3, Lihong Lai1, Honglei Wang1. 1. Department of Cardiology, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003, China. 2. Department of Pain, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003, China. 3. Department of Cardiology, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003, China. Electronic address: dongpingshuanly@yeah.net.
Abstract
BACKGROUND AND AIMS: Circulating cystatin C has been recognized as an independent predictor of cardiovascular and all-cause mortality in the general population. We aimed to evaluate the prognostic value of baseline circulating cystatin C levels in people with suspected or established coronary artery disease (CAD) by conducting a meta-analysis. METHODS: We searched Pubmed and Embase databases up to October 2016 for prospective observational studies investigating the predictive value of elevated circulating cystatin C levels in people with suspected or established CAD. Adverse vascular outcomes included all-cause mortality, cardiovascular mortality, or total adverse vascular events consisting of death, myocardial infarction, revascularization, stroke, and heart failure. RESULTS: Ten studies involving participants with known or suspected CAD were included in this meta-analysis. When comparing the highest with the lowest cystatin C levels, the pooled hazard ratio (HR) was 2.27 (95% confidence interval [CI] 1.86-2.78) for all-cause mortality, 2.24 (95% CI 1.69-2.97) for cardiovascular mortality, and 1.87 (95% CI 1.57-2.24) for total adverse vascular events, respectively. Subgroup analysis results showed that this association was not influenced by follow-up duration, region, or CAD type. CONCLUSIONS: Elevated circulating cystatin C is independently associated with adverse vascular outcomes in people with suspected or established CAD in terms of all-cause mortality, cardiovascular mortality, and total adverse vascular events. This increased risk is probably independent of creatinine/estimated glomerular filtration rate.
BACKGROUND AND AIMS: Circulating cystatin C has been recognized as an independent predictor of cardiovascular and all-cause mortality in the general population. We aimed to evaluate the prognostic value of baseline circulating cystatin C levels in people with suspected or established coronary artery disease (CAD) by conducting a meta-analysis. METHODS: We searched Pubmed and Embase databases up to October 2016 for prospective observational studies investigating the predictive value of elevated circulating cystatin C levels in people with suspected or established CAD. Adverse vascular outcomes included all-cause mortality, cardiovascular mortality, or total adverse vascular events consisting of death, myocardial infarction, revascularization, stroke, and heart failure. RESULTS: Ten studies involving participants with known or suspected CAD were included in this meta-analysis. When comparing the highest with the lowest cystatin C levels, the pooled hazard ratio (HR) was 2.27 (95% confidence interval [CI] 1.86-2.78) for all-cause mortality, 2.24 (95% CI 1.69-2.97) for cardiovascular mortality, and 1.87 (95% CI 1.57-2.24) for total adverse vascular events, respectively. Subgroup analysis results showed that this association was not influenced by follow-up duration, region, or CAD type. CONCLUSIONS: Elevated circulating cystatin C is independently associated with adverse vascular outcomes in people with suspected or established CAD in terms of all-cause mortality, cardiovascular mortality, and total adverse vascular events. This increased risk is probably independent of creatinine/estimated glomerular filtration rate.
Authors: Patricia Garcia-Garcia; Raquel Castejon; Pablo Tutor-Ureta; R A Silvestre; Susana Mellor-Pita; Carlos Jimenez-Ortiz; Miguel Yebra-Bango Journal: Clin Rheumatol Date: 2017-09-15 Impact factor: 2.980
Authors: Tracy L Schumacher; Christopher Oldmeadow; Don Clausen; Loretta Weatherall; Lyniece Keogh; Kirsty G Pringle; Kym M Rae Journal: Healthcare (Basel) Date: 2017-10-14
Authors: Qing Hao; Rebecca F Gottesman; Ye Qiao; Li Liu; Richa Sharma; Elizabeth Selvin; Kunihiro Matsushita; Josef Coresh; Bruce A Wasserman Journal: Neurology Date: 2020-04-17 Impact factor: 9.910
Authors: Ali Danesh; Heather C Inglis; Mohamed Abdel-Mohsen; Xutao Deng; Avril Adelman; Kenneth B Schechtman; John W Heitman; Ryan Vilardi; Avani Shah; Sheila M Keating; Mitchell J Cohen; Evan S Jacobs; Satish K Pillai; Jacques Lacroix; Philip C Spinella; Philip J Norris Journal: Front Immunol Date: 2018-05-08 Impact factor: 7.561